MSLN-Pep

MSLN-Pep is a 9-mer mesothelin-binding peptide identified through phage display screening for the targeted treatment of mesothelin-overexpressing tumors, particularly pancreatic cancer. Developed by researchers at Kyungpook National University, the peptide selectively binds to mesothelin-high pancreatic cancer cells such as ASPC-1 and Panc-1. Upon binding, MSLN-Pep is internalized and has been shown to inhibit cell migration and invasion. It serves as a targeting moiety for therapeutic payloads; for instance, when conjugated to a proapoptotic peptide (KLA), the resulting MSLN-Pep-KLA conjugate exerts selective cytotoxicity against pancreatic cancer cells and sensitizes them to gemcitabine treatment.